The short in vivo lifespan of many cytokines can make measurement of in vivo cytokine production difficult. A method was developed to measure in vivo IL-4 and IFN-γ production that eliminates this problem. Mice are injected with a biotin-labeled neutralizing IgG anti-IL-4 or anti-IFN-γ mAb and bled 2-24 h later. Secreted cytokine is captured by the biotin-labeled mAb to produce a complex that has a relatively long in vivo half-life and consequently accumulates in serum. Serum concentrations of the complex are determined by ELISA, using wells coated with an antibody to a second epitope on the same cytokine to capture the complex. This technique is specific and increases sensitivity of detection of secreted IL-4 at least 1000-fold. The amount of cytokine measured is directly proportional to the amount produced and relatively independent of the site of cytokine production. Furthermore, because mice are injected with small quantities of biotin-labeled anti-cytokine mAb, which sample, rather than neutralize, all secreted cytokines, cytokine-dependent responses are not inhibited. The in vivo half-lives of the cytokine-anti-cytokine mAb complexes are sufficiently short to allow cytokine production to be measured every 2-3 days in the same mice. Thus, use of this assay provides a practical and relatively simple and inexpensive way to measure ongoing in vivo cytokine production. Furthermore, the techniques that have been developed to measure in vivo production of IL-4 and IFN-γ can be applied to in vivo measurement of other molecules that have a short in vivo lifespan, including other cytokines.
Introduction
Because the nature of an immune response is controlled, to whether cytokine production by cells re-stimulated in vitro always correlates well with cytokine production in vivo. Furthera considerable extent, by cytokines produced during the response (1), characterization of cytokine production is more, methods that measure cytokine mRNA or depend on in vitro re-stimulation to measure cytokine protein generally important for understanding the nature of the response. Several techniques have been developed to determine cytorequire the sacrifice of a group of animals at each time point measured, as well as the sacrifice of an additional group if it is kine production, which measure cytokine mRNA expression or cytokine protein synthesis or secretion (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) . Limitations desired to correlate cytokine responses with another biological response. Consequently, large numbers of experimental of these techniques include the possibilities that cytokine mRNA levels may not correlate well with levels of cytokine animals frequently must be used in such studies. It would be preferable, in many circumstances, if measureprotein production and that cellular cytokine protein content may not correlate well with cytokine secretion. In addition, ment of serum cytokine levels could be used to determine cytokine production. Unfortunately, many cytokines, such as because ex vivo cytokine production by cells from immunized animals is often below detectable levels, it is frequently IL-4, are produced in such small amounts and are so rapidly excreted, catabolized or utilized that the quantities that necessary to re-stimulate immune cells in vitro with antigen or mitogen to reveal their capacity to produce cytokine accumulate in serum are undetectable by available assay systems (12) . (4, 7, 8, 11) . These techniques work well to increase cytokine production to detectable levels; however, it is not known The studies described here were designed to develop and test a method that had the advantages of measuring serum 24G2.3) (22) or IL-3 (MP2-43D11) (24) were obtained from the ATCC with the permission of DNAX (Palo Alto, CA) and cytokine levels, but would increase the in vivo lifespan of cytokines by inhibiting their utilization, catabolism and renal the assistance of Dr Robert Coffman. A hybridoma that produces a non-neutralizing rat IgG anti-IFN-γ mAb (AN-18) excretion. Because previous studies have demonstrated that preformed complexes of cytokines with neutralizing anti- (25) was a gift of Dr Anne O'Garra (DNAX). All of these hybridomas were grown as ascites in Pristane-primed athymic cytokine mAb can have a considerably longer in vivo lifespan than the free cytokines (12), we examined whether the injection nude mice. All mAb were purified from ascites by ammonium sulfate precipitation and ion-exchange chromatography as of mice with a small quantity of a neutralizing anti-cytokine mAb could 'capture' the cytokine and cause it to accumulate described, using isotype-specific anti-rat Ig antisera (ICN, Aurora, OH) and gel double-diffusion analysis to identify in serum. This might cause serum cytokine levels to increase in proportion to their production, so that relative rates of in vivo antibody-rich fractions. AECM-Ficoll was purchased from Biosearch (San Raphael, CA). Alkaline phosphatase conjugcytokine production could be determined by measuring serum concentrations of cytokine-anti-cytokine mAb complexes by ated to streptavidin was purchased from Jackson ImmunoResearch (West Grove, PA). Purified, recombinant mouse IL-4 ELISA. Results of our studies demonstrate that this in vivo assay, which we have named the Cincinnati cytokine capture was a generous gift of the Schering-Plough Research Institute (Kenilworth, NJ), recombinant mouse IL-3 and IFN-γ were assay (CCCA), provides an accurate and efficient way to measure relative in vivo IL-4 production and that a modification generous gifts of PharMingen (La Jolla, CA), and purified, recombinant mouse IL-12 was a generous gift of Hoffman of the same assay can measure in vivo production of IFN-γ.
LaRoche (Piscataway, NJ). AECM-Ficoll and some mAb were biotin-conjugated, using biotin N-hydroxy-succinimide Methods (Calbiochem-Behring, La Jolla, CA), as described (26), at a 1:10 (w/w) biotin:protein ratio. Mice ELISA BALB/c and C57BL/6 female mice and athymic nude male mice were purchased from the NCI (Bethesda, MD), and
Immulon II 96-well microtiter plates (Dynatech, Chantilly, VA) used at 8-16 weeks of age. C57BL/6.IL-4-deficient mice were incubated at room temperature for 2 h with 10 µg/ml of (13) were originally obtained form Dr Herbert Morse (NIH, the appropriate non-neutralizing anti-cytokine mAb in 0.1 M Bethesda, MD) and C57BL/6.IFN-γ-deficient mice (14) were Tris, pH 8.3. Plates were then washed 10 times with deionized originally purchased from Jackson (Bar Harbor, ME). C57BL/ H 2 O, using a Microwash II microtiter plate washer (Skatron, 6.IL-4-deficient and C57BL/6.IFN-γ-deficient mice were bred Sterling, VA) and blocked overnight at 4°C using 5% Carnation to each other to produce mice doubly deficient in IL-4 and non-fat dry milk powder and 0.2% NaN 3 in 0.1 M Tris, pH 8.3 IFN-γ on a C57BL/6 background. Offspring of these matings (5% milk buffer). To titer sera for a cytokine-anti-cytokine mAb were genotyped by PCR for IL-4 and IFN-γ (15) . The IL-4 complex, 25 µl of serial 4-fold dilutions of sera (starting with PCR used 5Ј-GCACAGAGCTATTGATGGGTC-3Ј, 5Ј-GCTundiluted sera or sera diluted 1:2, 1:4 or 1:10 with 0.1M Tris, GTGAGGACGTTTGGC-3Ј and 5Ј-TCAGGACATAGCGTTpH 8.3, supplemented with 0.25% Carnation non-fat dry milk GGC-3Ј as primers. The wild-type IL-4 allele yielded a 444 powder, 0.2% NaN 3 and 0.05% Tween 20) (MBTA) was added bp product, while the neo-disrupted allele yielded a 576 bp in duplicate to the microtiter plate wells. After 30 min, all wells product with a faint band at 1577 bp. The IFN-γ PCR used were filled with MBTA, using a Nunc Immunowash 12 hand 5Ј-AGAACTAAGTGGAAGGGCCCAGAAG-3Ј, 5Ј-AGGGAAwasher (Nunc, Kamstrup, Denmark), aspirated and filled with ACTGGGAGAGGAGAAATAT-3Ј and 5Ј-TCAGCGCAGGGG-MBTA, then washed 10 times with deionized H 2 O in the CGCCCGGTTCTTT-3Ј as primers. The wild-type IL-4 allele microtiter plate washer. Plates were then filled with MBTA and yielded a 220 bp product, while the neo-disrupted allele incubated for 5 min at room temperature, and again washed yielded a 1150 bp product. Mice that selectively express an with deionized water. Similar MBTA/deionized water wash IL-4 transgene in their lungs and background controls (16) steps were performed after every subsequent incubation with were a gift of Dr Jeffery Whitsett (Children's Hospital Research a reagent. Alkaline phosphatase-streptavidin (25 µl diluted Foundation, Cincinnati, OH).
1:2000 in MBTA) was then added to wells, plates were incubated for 1 h at room temperature and again washed. To Antibodies and immune reagents increase ELISA sensitivity, incubation of wells with alkaline phosphatase-streptavidin was followed by incubation with Goat anti-mouse IgD antibody (GaMδ) and normal goat IgG were produced as described (17). Hybridomas that produce 25 µl of biotin-AECM-Ficoll (1 µg/ml in MBTA), washing and a second incubation with alkaline phosphatase-streptavidin. with a biotin-labeled neutralizing anti-cytokine antibody, which binds secreted cytokine and prevents its excretion, utilization or degradation. The biotin-anti-cytokine antibody-cytokine complex is detected by ELISA, using an antibody to a second epitope on the same cytokine molecule to bind the biotin-anti-cytokine antibody-cytokine complex and enzyme linked to streptavidin, followed by a chromogenic substrate for that enzyme, to detect the bound complex.
standard contained 100 pg/ml of recombinant mouse IL-4 mAb complex by protecting it from utilization by preventing binding to cellular cytokine receptor, from renal excretion and and 15 ng/ml of biotin-BVD4-1D11; our IFN-γ standard contained 1 ng/ml of recombinant mouse IFN-γ and 150 ng/ml of from catabolism. If the injected anti-cytokine mAb is biotinlabeled, the serum concentration of the cytokine-anti-cytokine biotin-R46A2. Then 25 µl of the appropriate standard was added to microtiter plate wells and five serial 4-fold dilutions mAb complex can be determined by ELISA, using microtiter plate wells coated with a second antibody that binds to a of the standard were performed. Plates were further treated as described for sera. Titers were determined as the serum different epitope on the same cytokine molecule to capture the biotin-anti-cytokine mAb-cytokine complex and detecting dilution or cytokine concentration that would elicit a given A 405 after a prescribed incubation period. Serum cytokine the bound complex with enzyme linked to streptavidin, followed by addition of a chromogenic substrate for the enzyme concentrations were determined by comparing serum titers to titers obtained for a known cytokine concentration.
and determination of the concentration of the colored product with a microtiter plate ELISA reader that is set for the approSince the experiments described in this paper were performed, five changes have been made in our ELISA protocol priate wavelength. This process is illustrated in Fig. 1 . that lower background and decrease the time required for the assay without decreasing its sensitivity. (i) Milk buffer is Results centrifuged for 10 min at 1000 r.p.m. to remove insoluble material. (ii) Azide is omitted from all buffers, which are now
The CCCA increases the sensitivity of measurement of in vivo prepared weekly and stored at 4°C. (iii) ELISA plates are IL-4 production incubated for 1 h at 37°C, instead of 30 min at room temperature, after adding serum dilutions. (iv) The incubation
To stimulate in vivo IL-4 production, BALB/c mice were injected i.v. with saline or with 800 µg of affinity-purified GaMδ, with biotin-AECM-ficoll and the second incubation with streptavidin-alkaline phosphatase are no longer performed. (v) The which stimulates peak IL-4 production 5-6 days after antibody injection (2) . To determine if in vivo capture of secreted IL-4 starting concentration of the IL-4 standard is now 1 ng/ml instead of 100 pg/ml.
by a biotin-labeled anti-IL-4 mAb would make it easier to detect IL-4 in serum, mice injected 5 days earlier with saline Serum IgE levels were also determined by ELISA, as previously described (27) . or with GaMδ were injected i.v. with 10 µg of biotin-BVD4-1D11 (anti-IL-4) and bled 1 day later. As a control, GaMδ-injected Assay strategy and description mice were bled 1 day after they had received biotin-labeled anti-IL-5 mAb (TRFK-5) or no additional treatment. Serum The CCCA is based on the idea that an injected, neutralizing anti-cytokine mAb will complex with a secreted cytokine and levels of IL-4 were determined by ELISA, using microtiter plates coated with the non-neutralizing anti-IL-4 mAb, BVD6-cause it to accumulate in blood as a cytokine-anti-cytokine later were~7 pg/ml. Serum IL-4 levels increased Ͼ4000-fold if conventional mice were injected i.v. with 10 µg of anti-CD3 mAb 2 h before i.v. injection of 10 µg of biotin-anti-IL-4 mAb and were bled 2 h after the second injection. In contrast, no IL-4 (Ͻ3 pg/ml) was detectable in the serum of anti-CD3 mAb-immunized, biotin-anti-IL-4-treated, IL-4-deficient mice.
In vivo production of IL-4 is optimally detected by injection of 10 µg of biotin-anti-IL-4 mAb
Our initial experiments arbitrarily injected mice with a 10 µg dose of anti-IL-4 mAb to capture secreted IL-4. To determine if a higher or lower dose of anti-IL-4 mAb would improve as in mice injected with 50 µg of biotin-anti-IL-4 mAb, but were significantly lower in mice injected with 2 µg of biotin-anti-IL-4 mAb. Because of this result, a 10 µg dose of biotin-anti-IL-4 mAb was used in all subsequent experiments. 24G2.3, as described above, with the exception that an extra step was performed: biotin-BVD4-1D11 was added to all CCCA detection of IL-4 is proportional to the quantity of IL-4 wells after addition of sera to detect bound IL-4 because only injected into mice and is largely independent of the site of some mice had received this mAb in vivo. Results of this IL-4 injection study (Fig. 2) demonstrate that~25 pg/ml of IL-4 was detected in unimmunized mice that received biotin-anti-IL-4 mAb, while
To determine if the concentration of serum IL-4 detected by the CCCA is proportional to the amount of IL-4 secreted and GaMδ treatment caused IL-4 captured by biotin-anti-IL-4 to increase~100-fold. No IL-4 (Ͻ7 pg/ml) was detectable in if the site of IL-4 secretion influences the quantity of IL-4 detected, unimmunized mice were injected i.v. with 10 µg of unimmunized or GaMδ-immunized mice that had received no biotin-labeled mAb or biotin-anti-IL-5. Thus, the in vivo capture biotin-anti-IL-4 mAb and, 1 h later, i.v., i.p. or s.c. with 1000, 250 or 63 ng of recombinant IL-4. Mice were bled 4 h after of IL-4 with biotin-anti-IL-4 mAb increases the ability to detect in vivo IL-4 production by Ͼ300-fold.
IL-4 injection and serum IL-4 levels were determined by ELISA (Fig. 5) . Results demonstrated that serum IL-4 levels were Cytokine detection by the CCCA is specific proportional to the quantity of IL-4 injected and were not influenced to any appreciable extent by the route of IL-4 To determine the specificity of the CCCA for IL-4, we measured serum IL-4 levels, as stimulated by anti-CD3 mAb treatment injection. These observations suggest that the CCCA can be used to measure IL-4 production and that IL-4 produced at (28), in C57BL/6 wild-type and IL-4-deficient mice (Fig. 3) . group of anti-IgD mAb-immunized mice that was never treated with anti-IL-4 mAb were bled 8 days after anti-IgD mAb injection and serum IgE levels were determined by ELISA. Results of this experiment (Fig. 7) demonstrate that serum IL-4 levels slowly increased, starting 2 days after anti-IgD the three different sites tested should be detectable. To further examine this last point, we investigated whether the CCCA mAb injection, peaked at day 5 and started to decrease by day 6. Similar IgE levels were observed in all groups of mice. could detect increased IL-4 production in mice in which a transgene that induces increased IL-4 production is regulated These results demonstrate that the same mice can be injected more than once to determine IL-4 production at different by a lung-specific, Clara cell-derived, promoter that causes IL-4 to only be produced in the lungs (IL-4 LTgn mice) (16) .
timepoints and that even multiple injections of biotin-anti-IL-4 mAb do not influence the magnitude of an IL-4-dependent Serum IL-4 levels, as detected by the CCCA, were~100-fold greater in biotin-anti-IL-4 mAb-treated IL-4 LTgn mice than in response. similarly treated wild-type mice and were not detectable in
The CCCA can be used to specifically measure IFN-γ prountreated IL-4 LTgn mice (Fig. 6) . Thus, the CCCA can detect duction IL-4 that is produced at different sites of the body.
To determine if the CCCA technique could be used to measure The CCCA can be used to detect IL-4 secretion at multiple cytokines besides IL-4, we used a similar procedure to the timepoints in the same mouse and does not affect IL-4-IL-4 CCCA to measure in vivo production of IFN-γ. Anti-CD3 dependent biological responses mAb-treated BALB/c mice were injected with 10-160 µg of biotin-anti-IFN-γ mAb (R46A2) at the time of anti-CD3 mAb Because preformed IL-4-anti-IL-4 mAb complexes have an in vivo half-life of~1 day (12), we expected that it might be treatment and bled 4 h later. Results showed near maximal were determined by ELISA as described above; serum IL-3 levels 10 µg of anti-CD3 mAb (2C11) plus 10, 40 or 160 µg of biotin-antiwere determined by ELISA using microtiter plates coated with an IFN-γ mAb (R46A2) and bled 4 h later. Serum IFN-γ levels were anti-IL-3 mAb (MP2-43D11) that binds an IL-3 epitope different from determined by ELISA, using microtiter plates coated with a mAb (ANthat bound by MP2-8F8. 18) that binds to a different IFN-γ epitope than that bound by R46A2. similar small quantities of IL-4, but no IFN-γ, were detectable in IL-4/IFN-γ-double-deficient mice. These results indicate that the CCCA can be used to measure the production of more than one cytokine at the same time, with the stipulation that IFN-γ detection at a 40 µg dose but considerably less IFN-γ detection at a 10 µg dose (Fig. 8, upper panel) . Doses of attempted measurement of multiple cytokines increases the background for detection of IL-4, so that small amounts of IL-4 50 µg of biotin-anti-IFN-γ mAb were injected in subsequent experiments. At this dose, serum IFN-γ was detectable in appear to be made even when IL-4 production is truly absent. unimmunized BALB/c mice and increased~1000-fold in anti-IL-12 enhances IFN-γ production and suppresses IL-4 produc-CD3 mAb-immunized mice (Fig. 8, middle panel) . No IFN-γ tion in GaMδ-treated mice was detected in the serum of anti-CD3 mAb-immunized C57BL/6.IFN-γ-deficient mice (Fig. 8, lower panel) .
To determine if the CCCA could be used to detect a shift in cytokine production during an immune response, we used it The CCCA can simultaneously detect production of more than to examine the effects of IL-12 on GaMδ-treated mice. Previous one cytokine in the same mouse studies, which used RT-PCR to characterize in vivo cytokine gene expression, demonstrated that GaMδ induces a larger An assay that could be used to simultaneously detect the production of more than one cytokine in the same mouse percentage increase in IL-4 than IFN-γ mRNA expression and that the relative production of these two cytokines is reversed would be more efficient and would use fewer animals than one that could only detect a single cytokine in one animal. To if mice are simultaneously treated with IL-12 (29) . CCCA detected a 9-fold increase in serum IL-4 concentration and a determine whether the CCCA could be used to simultaneously detect production of three cytokines, C57BL/6 wild-type, 3-fold increase in serum IFN-γ concentration 6 days after immunization of BALB/c mice with 400 µg of GaMδ plus IL-4-deficient, IFN-γ-deficient and IL-4/IFN-γ-double-deficient mice were simultaneously injected i.v. with 10 µg of anti-CD3 400 µg of normal goat IgG. The magnitude of the increase in IL-4 production was probably greater than was revealed by mAb, 10 µg of biotin-anti-IL-4 mAb, 50 µg of biotin-anti-IFN-γ mAb and 25 µg of biotin-anti-IL-3 mAb, and bled 4 h later.
the assay, because simultaneous measurement of IL-4 and IFN-γ increases background IL-4 determinations, as noted Results of this experiment (Fig. 9 ) demonstrated that all three cytokines were detected in wild-type mice, and that IL-3 and above. Consistent with previous RT-PCR data (29), daily strength of the CCCA is the direct relationship between quantity of cytokine secreted (or injected) and quantity detected, there is not necessarily a 1:1 proportionality between these two parameters. As the quantity of cytokine secreted increases, the percent that is bound by anti-cytokine antibody may decrease, because of a decreasing ratio of secreted cytokine to injected anti-cytokine mAb, or increase, because of increasing saturation of cell membrane and secreted indicate that this technique can be used, at least qualitatively, to detect changes in cytokine production. A fifth limitation of the CCCA is that it would probably be less practical to use in larger animals than in mice. Assuming treatment of GaMδ-immunized mice with 500 ng/day of IL-12, starting on the day of GaMδ-injection reversed the cytokine that the quantity of biotin-anti-cytokine mAb needed to detect cytokine production is proportional to an animal's extracellular nature of the response by decreasing serum IL-4 levels by a factor of 3.6 and causing a 152-fold increase in serum IFN-γ fluid volume, the expense of performing the CCCA would be considerably greater in large animals than in mice. The levels (Fig. 10) . Thus, the CCCA can be used to 'T h -type' cytokine responses and detect the in vivo effects of immunorequirement to inject foreign mAb would make the CCCA particularly difficult to use in humans, unless anti-cytokine modulators on cytokine production.
antibodies or soluble cytokine receptors were already being administered for a different diagnostic or a therapeutic Discussion purpose. Despite all of these limitations, the ease of use of the CCCA Our observations demonstrate that the CCCA is a simple, objective, sensitive and specific technique for the measureand its ability to repeatedly measure whole body in vivo cytokine secretion should make it a valuable tool for small ment of in vivo cytokine secretion. Use of this technique avoids the potential problems of measuring cytokine mRNA animal studies, particularly as CCCA for additional cytokines are developed. Our recent, surprising observations that Stat6-as a substitute for cytokine protein, measuring intracellular cytokine content as a substitute for cytokine secretion or deficient mice can make normal type 2 cytokine responses to some antigens (30, 31) provides an example of the usemeasuring cytokine secretion after ex vivo re-stimulation as a substitute for in vivo secretion. In addition, the ability to fulness of the CCCA in a setting in which different results have been obtained from standard in vitro assays of cytokine repeatedly measure cytokine secretion in the same mice, without interfering with an ongoing cytokine-dependent production (32-34). The usefulness of the CCCA in obtaining these results suggests that this assay may have general utility immune response, can, in some experiments, considerably decrease experimental animal requirements and costs.
in the detection and quantitation of other secreted molecules that have a short in vivo lifespan, including cytokines other The CCCA does, however, have limitations. First, it does not reveal the identity of cytokine-secreting cells. Secondly, than IL-4 and IFN-γ, and some polypeptide hormones and secreted tumor antigens. foreign anti-cytokine mAb can elicit antibody responses that prevent their capture of secreted cytokine. This can cause false negative results in some studies if mice are repeatedly injected with the mAb for Ͼ10 days (data not shown). Thirdly, Acknowledgements some anti-cytokine mAb react with each other in ways that of cytokine secretion may not be possible. Although one
